Also: All the news and watercooler chat from Fortune.

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.

Jan 27 (Reuters) - The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

LONDON (Reuters) -European and U.S. healthcare stocks surged on Wednesday, propelled by a deal between Pfizer and President Donald Trump to lower prescription drug prices in the Medicaid programme in ...